Received: from apserver4.Arizeke.com ([188.8.131.52])
by www.munged.ext (8.11.6/8.11.6) with ESMTP id h0FGGXg09560
for <email@example.com>; Wed, 15 Jan 2003 11:16:34 -0500
Received: from mailbox.pink-shoes.nu (184.108.40.206 [220.127.116.11]) by apserver4.Arizeke.com with SMTP (Microsoft Exchange Internet Mail Service Version 5.5.2653.13)
id CQGGAZCP; Wed, 15 Jan 2003 01:52:13 -0800
From: "Daniel" <firstname.lastname@example.org>
Subject: People Work Differently24060
Date: Wed, 15 Jan 2003 02:02:46 -2000
BioCurex PRESS RELEASE
Source: BioCurex, Inc.
January 9, 2003
OTCBB Listed BioTech Companies BOCX & RJVN -
Creating a Non-Toxic Therapeutic Antibody Cancer
Treatment That May Arrest Development and Replication
of Cancerous Cells.
Rancho Santa Margarita, Calif., January 9, 2003 BioCurex,
Inc., (OTC BB:BOCX), Announces further developments
relating to its licensing agreement with BioKinetix,
a company being acquired by RJV Networks, Inc.,
(OTC BB : RJVN).
BioCurex and RJV networks (through Biokinetix) are
behind the development of a new therapeutic product,
which experts believe will arrest the development of
and replication of cancerous cells that cause the
growth of malignant tumors.
BOCX's proprietary technology has identified a New
Widespread Cancer marker Molecule named RECAF.
Cancer "markers" are molecules that appear on cancer
cells but not on normal cells and have been hailed as
The Holy Grail of cancer research since they can be
used to detect (diagnose) and then specifically target
cancer cells (therapy) - offering the potential to
provide treatment of cancer by delivering antibodies
to the targeted cancerous cells.
RJVN and BioKinetics have proprietary technology for
developing "superantibodies", an enhancement of antibody
technology that makes ordinary antibodies much more lethal.
The combination of anti-RECAF antibodies from BioCurex with
the superantibody technology from RJVN - BioKinetics is
expected to produce a powerful therapeutic agent to combat
most types of cancer.
If the antibodies prove to be cancer cell specific, it
is unlikely that there would be any adverse side effects.
This lack of toxicity should accelerate testing and
Dr. Moro, President of Biocurex stated: "Our ultimate
goal is to fight cancer. We have the cancer marker that
identifies the cancer cells and RJV Networks-BioKinetix
has the superantibody technology to kill them. It is only
natural that we join forces in the battle against this
horrible disease. I see tremendous potential for success
in this joint effort.
Dr. John Todd, President of BioKinetix Corporation stated
that Bio Kinetix Corporation's mission is to acquire
intellectual property rights for existing products
and intellectual property. Then, through a series of
collaborative relationships, we will facilitate the
development of a new generation of monoclonal antibodies
(termed "Superantibodies), which will have a significantly
improved therapeutic potency as anticancer agents.
Richard Moro, President
For more info see RJVN and BOCX in the news.
You can also see this Press Release at Yahoo Finance
You can also look them up by their symbols:
OTC BB:BOCX or OTC BB : RJVN
**** Special Financial-Stock Opt-in mailing list Offer ****
As a member of our special opt-in mailing list, you will
be among the first to receive up to the minute information
regarding the companies we profile above as well as a
free 10-day trial to a website with real-time Level II quotes,
research reports, OTC BB promo / syndication calendar,
trading chat rooms, full threading message boards, along
with many other valuable and free investment tools not
readily available to the general public. This is an
incredible opportunity! Just click the link below to
send us an email, and you will be immediately added to
our Opt-in list. Please be sure that "opt-in" is in the
subject line of the email. If opt-in is not in the subject line
you will not be added.
**See Removal instructions below
Information within this email contains "forward looking
statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21B of the Securities
Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, goals,
expectations, beliefs, plans, projections, objectives,
assumptions or future events or performance are not
statements of historical fact and may be "forward
Forward looking statements are based on expectations,
estimates and projections at the time the statements
are made that involve a number of risks and uncertainties
which could cause actual results or events to differ
materially from those presently anticipated. Forward
looking statements in this action may be identified
through the use of words such as: "projects", "foresee",
"expects", "estimates," "believes," "understands" "will,"
"anticipates," or that by statements indicating certain
actions "may," "could," or "might" occur. All information
provided within this email pertaining to investing, stocks,
securities must be understood as information provided and
not investment advice. Emerging Equity Alert advises all
readers and subscribers to seek advice from a registered
professional securities representative before deciding to
trade in stocks featured within this email. None of the
material within this report shall be construed as any
kind of investment advice.
In compliance with the Securities Act of 1933,
Section 17(b), Emerging Stock Alert discloses the
receipt of 125,000 unrestricted shares of RJVN from
a third party for the publication of this report. Be
aware of an inherent conflict of interest resulting
from such compensation due to our intent to profit
from the liquidation of these shares. Shares may be
sold at any time, even after positive statements have
been made regarding the above company. All factual
information in this report was gathered from public
sources, including but not limited to SEC filings,
Company Press Releases, and Market Guide. Emerging
Equity Alert believes this information to be reliable
but can make no guarantee as to its accuracy or
completeness. Use of the material within this email
constitutes your acceptance of these terms.
****** Advertising Disclaimer ******
We are an Internet Advertising Company and have received
a monetary payment for this mailing service. We hold no
stocks and have no personal interest in this company
whatsoever. We are simply being paid to perform a service.
This message is a copy of a BioCurex press release.
****** Removal Instructions ******
This message has been sent to you in compliance with
our strict anti-abuse regulations. We will continue to
bring you valuable offers on the products and services
that interest you most. If you do not wish to receive
further mailings, please click below. We respect all
removal requests. To be removed immediately from our
mailing lists just click on the link below:
Be sure that "purge-me" is in the subject line
of the email prior to sending it.